转录组
肠道菌群
类风湿性关节炎
促炎细胞因子
人口
微生物群
炎症
生物
消炎药
免疫学
关节炎
趋化因子
医学
药理学
生物信息学
基因表达
基因
生物化学
环境卫生
作者
Liming Zhao,Kai Zheng,Xiaolin Wan,Qiang Xiao,Lin Yuan,Chuanfang Wu,Jinku Bao
出处
期刊:Heliyon
[Elsevier]
日期:2024-06-27
卷期号:10 (13): e33706-e33706
被引量:1
标识
DOI:10.1016/j.heliyon.2024.e33706
摘要
Rheumatoid arthritis (RA) is globally treated with several commercially available anti-inflammatory and analgesic drugs, which pose adverse side effects in many cases. Due to increasing population affected by autoimmune disorder of joints inflammation, it is crucial to use natural therapies, which are less toxic at metabolic level and promote gut health. In this study, we investigated the potential role of a locally developed traditional Chinese medicine (TCM), namely Duzheng tablet (DZGP) in controlling the RA. For this purpose, we introduced RA in male mice and divided them into 5 different groups. High throughput transcriptome analysis of synovial cells after DZGP treatment in arthritic mice revealed a significant alteration of gene expression. The correlation analysis of transcriptome with metabolites revealed that DZGP specifically targeted the B cells mediated immunity pathways. Treatment with DZGP inhibited the cytokines production, while reducing the production of inflammatory TNF-α, which led to the alleviation of inflammatory response in arthritic mice. Additionally, we applied integrated approach using 16S rDNA sequencing to understand the microbial population in relation to metabolites accumulation. The results showed that DZGP promoted the healthy gut microbiota by maintaining the ratio of Firmicutes and Bacteroidota and introduction of two additional phyla namely, Verrucomicrobiota and Cyanobacteria. Therefore, it is concluded that DZGP offers an advantage over commercial drug by changing the metabolic profile, gut microbiota while exhibiting lower cellular toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI